← All Abvc Biopharma, INC filings

Abvc Biopharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ABVC
Abvc Biopharma, INC
10-K: ABVC BioPharma Reports Zero Revenue, Increased Losses in 2025
ABVC BioPharma, Inc. reported a significant increase in net loss and no revenue for the fiscal year ended December 31, 2025, alongside ongoing clinical trial progress and efforts to address internal control weaknesses.
NASDAQ
ABVC
Abvc Biopharma, INC
10-K: ABVC BioPharma Reports Fiscal Year 2024 Results, Navigates Financial Challenges
ABVC BioPharma reports increased revenue for fiscal year 2024, but faces ongoing financial challenges and a restatement of prior year financials.
NASDAQ
ABVC
Abvc Biopharma, INC
10-K/A: ABVC BioPharma Files Amended Annual Report to Include Missing Exhibits
ABVC BioPharma has filed an amendment to its annual report on Form 10-K to include previously omitted exhibits related to insider trading policy and incentive compensation recovery.
NASDAQ
ABVC
Abvc Biopharma, INC
10-K: ABVC BioPharma Reports 2023 Financial Results, Highlights Pipeline Progress
ABVC BioPharma's 2023 annual report details a year of strategic shifts, pipeline advancements, and financial challenges, including a significant net loss and efforts to maintain Nasdaq listing compliance.